Peptides DB
Research-centric peptide and protocol reference hub
Study 46 of 46Orforglipron (LY-3502970) literaturebiorxiv-preprint · Meta-analysis · Phase 22026

Safety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trials

Oral GLP-1 receptor agonists may significantly reduce body weight and improve metabolic outcomes in obese patients, but they are also associated with a higher risk of gastrointestinal side effects.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
14
Preclinical
9
Observational
1
Open-label
14
Randomised
8
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated the safety and efficacy of oral GLP-1 receptor agonists in non-diabetic obese patients. The analysis included six randomized controlled trials comparing these agonists to placebo, with significant reductions in body weight and metabolic outcomes observed. However, an increased risk of adverse events was also noted.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%Phase 22026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Background</bold> Oral glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed as a needle-free alternative of subcutaneous injectables GLP-1 RAs. This systematic review and meta-analysis evaluated whether oral GLP-1 receptor agonists improve body weight and metabolic outcomes, and characterized their safety and tolerability, compared with placebo in adults with obesity or overweight. <bold>Methods</bold> PubMed, Embase, the Cochrane Library, Scopus, and ClinicalTrials.gov were systematically searched for randomized controlled trials comparing oral GLP-1 receptor agonists with placebo in adults with obesity or overweight without diabetes. Study selection followed Cochrane handbook guidelines and PRISMA checklist 2020, and quality was assessed using the Cochrane RoB 2 tool. Analysis was done using random-effects models in R version 4.5.2 (meta package). Certainty of evidence was assessed using the GRADE framework. <bold>Results</bold> Six randomized controlled trials comprising 31 treatment arms of five oral GLP-1 receptor agonists (danuglipron, elecoglipron, lotiglipron, orforglipron, and aleniglipron) versus placebo were included, spanning phase 2 to phase 3 designs of 26 to 72 weeks. Four trials had a low risk of bias, one raised some concerns, and one had a high risk. Oral GLP-1 receptor agonists significantly reduced body weight from baseline compared with placebo (MD −7.61%, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%), an effect that remained stable on leave-one-out sensitivity analysis and differed significantly by drug, escalation intensity, and placebo run-in. Significant reductions were also observed for alanine aminotransferase (MD −9.53 U/L, 95% CI −11.88 to −7.18; p<0.0001; I²=0%), aspartate aminotransferase (MD −5.48 U/L, 95% CI −6.99 to −3.97; p<0.0001; I²=0%), systolic blood pressure (MD −5.49 mmHg, 95% CI −6.17 to −4.82; p<0.0001; I²=0%), and diastolic blood pressure (MD −1.54 mmHg, 95% CI −1.99 to −1.09; p<0.0001; I²=8.6%). However, oral GLP-1 receptor agonists were associated with an increased risk of any adverse event (RR 1.07, 95% CI 1.04–1.11; p<0.0001), treatment discontinuation due to adverse events (RR 2.85, 95% CI 2.07–3.92; p<0.0001), nausea (RR 3.04, 95% CI 2.29–4.04; p<0.0001), vomiting (RR 3.38, 95% CI 2.19–5.21; p<0.0001), constipation (RR 2.48, 95% CI 1.64–3.75; p<0.0001), and gastroesophageal reflux (RR 1.92, 95% CI 1.15–3.19; p=0.0124), with no significant differences in diarrhea, dyspepsia, headache, or fatigue. Heterogeneity was low (I²≤8.6%) for all outcomes except body weight. GRADE certainty of evidence was high for seven outcomes and moderate for the remaining eight, with no outcome rated below moderate certainty. <bold>Conclusion</bold> Oral GLP-1 receptor agonists significantly reduce body weight and improve liver enzymes and blood pressure compared with placebo in adults with obesity or overweight, but are associated with a higher incidence of gastrointestinal adverse events and treatment discontinuation. </p>

Background

This paper addresses the efficacy and safety of oral GLP-1 receptor agonists as an alternative to injectable forms for weight management in obese individuals without diabetes. Prior studies have established the role of GLP-1 receptor agonists in weight loss, but the specific effects of oral formulations remain less understood. This systematic review and meta-analysis aims to clarify these effects and assess safety profiles.

Methods

The study employed a systematic review and meta-analysis design, including randomized controlled trials that compared oral GLP-1 receptor agonists to placebo. A total of six trials were included, with treatment durations ranging from 26 to 72 weeks. The analysis utilized random-effects models and assessed the quality of evidence using the GRADE framework.

Results

The primary endpoint revealed a significant reduction in body weight, with an MD of −7.61% compared to placebo (95% CI −8.59 to −6.62; p<0.0001). Additional significant reductions were noted in liver enzymes and blood pressure, with no significant differences in other adverse events except for gastrointestinal issues.

Interpretation

These findings suggest that oral GLP-1 receptor agonists can lead to meaningful weight loss and improvements in metabolic parameters compared to placebo. However, the clinical significance of the weight reduction may be tempered by the increased risk of gastrointestinal adverse events, which could affect patient adherence. The presence of trials with varying risk of bias and high heterogeneity in body weight outcomes also limits the robustness of the conclusions.

Key findings

  • MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%
  • MD −9.53 U/L alanine aminotransferase reduction vs placebo, 95% CI −11.88 to −7.18; p<0.0001; I²=0%
  • MD −5.48 U/L aspartate aminotransferase reduction vs placebo, 95% CI −6.99 to −3.97; p<0.0001; I²=0%
  • MD −5.49 mmHg systolic blood pressure reduction vs placebo, 95% CI −6.17 to −4.82; p<0.0001; I²=0%
  • RR 1.07 for any adverse event, 95% CI 1.04–1.11; p<0.0001
  • RR 2.85 for treatment discontinuation due to adverse events, 95% CI 2.07–3.92; p<0.0001

Limitations

  • High heterogeneity in body weight outcomes (I²=74.0%)
  • Included trials with varying risk of bias
  • Increased risk of gastrointestinal adverse events
  • Not all outcomes rated high certainty in evidence

Elsewhere in the Orforglipron (LY-3502970) corpus

AOrforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).JAMA · 2026 · Mean AHI change was -17.8 for orforglipron vs -4.5 for placebo in trial 1, difference -13.2 [95% CI, -17.7 to -8.7]; P < 0.001 at 52 weeks.HumanDOrforglipron for Obstructive Sleep Apnea: Research Summary.JAMA · 2026reviewAEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.HumanBPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes, obesity & metabolism · 2025 · n=800 · 84.2% preferred Treatment A vs 15.8% for Treatment B.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.Human